Researchers at Johns Hopkins University have launched another biotech that builds on more than a decade of investigation that they hope will improve T cell engagers and limit their off-tumor toxicities.
Bert Vogelstein, who founded companies like Thrive and Haystack Oncology, has been working with Drew Pardoll for years on mutation-associated neoantigens, or MANAs. They formed a biotech around the idea in 2020, naming it ManaT Bio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.